Showing results (71-80 of 148) with videos related to

Sort By:
Pageof 15
Psychopharmacology|January 1, 1985
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patientsA C Altamura, S H Curry, S Montgomery, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1987
Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in miceA C Altamura, F De Novellis, M C Mauri, et al.
Schizophrenia Research|December 31, 2002
Clinical variables related to suicide attempts in schizophrenic patients: a retrospective studyA C Altamura, R Bassetti, S Bignotti, et al.
Schizophrenia Research|October 12, 2001
Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective studyA C Altamura, R Bassetti, F Sassella, et al.
Clinical Neuropharmacology|February 15, 2017
The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic ReviewMassimiliano Buoli, Silvia Grassi, Valentina Ciappolino, et al.
Pharmacopsychiatry|January 9, 2003
Prescribing second-generation antipsychotics and the evolving standard of care in ItalyC Barbui, A Danese, G Guaiana, et al.
International Journal of Psychiatry in Clinical Practice|June 17, 2014
Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial respondersA C Altamura, I Velonà, R Curreli, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 8, 2001
Clinical and subclinical body dysmorphic disorderC Altamura, M M Paluello, E Mundo, et al.
Minerva Psichiatrica|January 1, 1991
[L-sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride]A C Altamura, M C Mauri, G Regazzetti, et al.
Psychopharmacology|January 1, 1983
Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implicationsA C Altamura, T Melorio, G Invernizzi, et al.
Pageof 15